Table of contents
Trial overview
The available study is a Phase 2 trial of ALXN2420 in people with acromegaly, a condition being studied in adults.[1] It is an interventional study, which means researchers assign the study treatment and compare results over time.[1]
The trial compares ALXN2420 with placebo, which is a look-alike treatment with no active study drug, and both are given together with somatostatin analogs.[1] The somatostatin analogs listed in the trial are octreotide acetate and lanreotide acetate.[1]
Who can participate
This study is designed for adult participants with acromegaly.[1] The brief summary says the treatment is being tested in adults who are already receiving somatostatin analog therapy.[1]
The trial includes a planned enrollment of 60 participants.[1] This number shows how many people the researchers planned to include in the study.[1]
What is being measured
The main endpoint, or main result the study wants to measure, is the percentage change from baseline in serum IGF-1 level at Week 15.[1] Baseline means the starting value before treatment begins, and serum IGF-1 is a blood marker used to follow disease activity in acromegaly.[1]
The brief summary states that the purpose of the study is to evaluate whether 15 weeks of ALXN2420 treatment can lower IGF-1 levels better than placebo when used with SSA therapy.[1] SSA therapy means treatment with somatostatin analogs.[1]
Trial status and design
The trial status is Suspended, so the study is not actively moving forward at the time shown in the source data.[1] The study is listed as interventional and uses a comparison between ALXN2420 and matching placebo.[1]
Only one trial was provided in the source data, so this article focuses on that single Phase 2 study in acromegaly.[1]
